Update on Capecitabine in Colorectal Cancer

Schmoll, Hans‐Joachim; Arnold, Dirk

doi:10.1634/theoncologist.11-9-1003

Cited by 32 publications

(22 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Overall, such data make a powerful case for the use of European-style 5-FU regimens. The possible role of capecitabine, with the potential advantages of oral administration, is extensively considered elsewhere in this volume [19].…”

Section: Bolus or Infusion?mentioning

confidence: 99%

Therapy for Metastatic Colorectal Cancer

Goldberg

2006

The Oncologist

View full text Add to dashboard Cite

Learning ObjectivesAfter completing this course, the reader will be able to:1. Compare toxicity profiles among combination chemotherapy programs for colorectal cancer.2. Identify median survival times for chemotherapy programs for colorectal cancer. AbstractMedian overall survival of metastatic colorectal cancer patients treated with first-and second-line combination chemotherapy now extends to more than 20 months in some studies. Chemotherapy alone, particularly when oxaliplatin is included, may allow potentially curative resection of advanced disease. There is evidence that the addition of antibodies targeted against vascular endothelial growth factor or the epidermal growth factor receptor will further improve prospects for patients with advanced and metastatic disease. However, the optimum sequencing of chemo-and biological therapies remains to be established, as does the potential contribution of numerous agents in development. The Oncologist 2006;11:981-987

show abstract

Section: Bolus or Infusion?mentioning

confidence: 99%

Therapy for Metastatic Colorectal Cancer

Goldberg

2006

The Oncologist

View full text Add to dashboard Cite

show abstract

“…Clinically, combination therapy has become a general approach to cancer treatment (35). The goal of combination therapy is to augment the antitumor effects and to reduce the side effects and toxicities of drugs to the fullest extent possible.…”

Section: Discussionmentioning

confidence: 99%

Combination of calcineurin B subunit (CnB) and 5‑fluorouracil reverses 5‑fluorouracil‑induced immunosuppressive effect and enhances the antitumor activity in hepatocellular carcinoma

et al. 2017

View full text Add to dashboard Cite

Abstract. Five-fluorouracil (5-FU) is a widely used chemotherapeutic agent for digestive system tumors; however, continuous use of 5-FU may cause severe side effects, including myelosuppression and immunosuppression. Our previous study revealed that calcineurin B subunit (CnB), an innovative genetic engineering antitumor protein, possesses tumor-suppressive effects with low toxicity. CnB can bind to and activate integrin αM on macrophages, subsequently promoting the expression, and secretion of TNF-related apoptosis-inducing ligand, a specific proapoptotic cytokine. In the present study, whether the combined use of CnB and 5-FU can reverse the myelosuppression, and immunosuppressive effects of 5-FU by reactivating the immune system thus increasing antitumor efficacy, was investigated. It was demonstrated that combined treatment of 5-FU and CnB led to increased tumor-suppressive effects, as indicated by reduced tumor volume and weight when compared with 5-FU or CnB treatment alone in a hepatoma xenograph model. In addition, it was demonstrated that combined treatment inhibited the proliferation of hepatoma cells. Notably, the addition of CnB to 5-FU-based therapy completely reversed the immunosuppressive effect of 5-FU. The spleen index and total number of white blood cells in the combination group were higher compared with that of the 5-FU alone group. Furthermore, pathological examinations indicated that CnB attenuated 5-FU-induced organ damage. Based on these findings, it is proposed that CnB may serve as a novel and promising drug candidate for the improvement of 5-FU-based chemotherapy.

show abstract

“…Capecitabine is an oral fluoropyrimidine. 38 Because it has been in use for far shorter time than 5-FU, the pharmacogenetics and pharmacogenomics are less well studied. Initial publications suggest that the characteristics of enzymes involved in the metabolism of 5-FU may have similar potential as markers.…”

Section: Markers For Fluoropyrimidinesmentioning

confidence: 99%